2nd Quarter - Report

TIBER CREEK HEALTH STRATEGIES, INC. for NOVARTIS

A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.

Firm
Client
Income
$60,000
Expenses
—

Versions of this report

Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.

Filing Filed Amount Counted
2nd Quarter - Report (this page) Jul 14, 2023 $60,000 Replaced
2nd Quarter - Amendment Jul 18, 2023 $60,000 Yes

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.

LobbyistCovered position, as disclosed
JAMES BRYANT HALL —

Contacted: SENATE

Bills named: S. 476 (118th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.